GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoVista Innovative Therapies Inc (OTCPK:OVIT) » Definitions » Earnings per Share (Diluted)

OVIT (OncoVista Innovative Therapies) Earnings per Share (Diluted) : $-0.14 (TTM As of Sep. 2015)


View and export this data going back to 2005. Start your Free Trial

What is OncoVista Innovative Therapies Earnings per Share (Diluted)?

OncoVista Innovative Therapies's Earnings per Share (Diluted) for the three months ended in Sep. 2015 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 was $-0.14.

OncoVista Innovative Therapies's EPS (Basic) for the three months ended in Sep. 2015 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2015 was $-0.14.

OncoVista Innovative Therapies's EPS without NRI for the three months ended in Sep. 2015 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2015 was $-0.15.


OncoVista Innovative Therapies Earnings per Share (Diluted) Historical Data

The historical data trend for OncoVista Innovative Therapies's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoVista Innovative Therapies Earnings per Share (Diluted) Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 -0.10 -0.08 -0.07 -0.12

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -0.07 -0.01 -0.05 -0.01

Competitive Comparison of OncoVista Innovative Therapies's Earnings per Share (Diluted)

For the Biotechnology subindustry, OncoVista Innovative Therapies's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoVista Innovative Therapies's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's PE Ratio distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's PE Ratio falls into.



OncoVista Innovative Therapies Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

OncoVista Innovative Therapies's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2014 is calculated as

Diluted Earnings Per Share (A: Dec. 2014 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.544-0)/21.651
=-0.12

OncoVista Innovative Therapies's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2015 is calculated as

Diluted Earnings Per Share (Q: Sep. 2015 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.326-0)/23.055
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


OncoVista Innovative Therapies  (OTCPK:OVIT) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


OncoVista Innovative Therapies Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of OncoVista Innovative Therapies's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoVista Innovative Therapies Business Description

Traded in Other Exchanges
N/A
Address
14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.
Executives
Alexander Ruckdaeschel director 123 EAST 83RD STREET, APT 3-B, NEW YORK NY 10028
Paul A Mieyal director C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830
Charles E Davidson 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp 10 percent owner 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Spectrum Trading Ltd 10 percent owner 411 WEST PUTNAM AVENUE, SUITE 125, GREENWICH CT 06830

OncoVista Innovative Therapies Headlines

No Headlines